Lafora disease (LD) is the major teenage-onset progressive myoclonus epilepsy (PME). Insidious cognitive decline and escalating myoclonic, visual, convulsive, and other seizures follow an initial decade of normal development. Within a few years, seizures are intractable, myoclonic absences are near constant, and a disinhibited dementia has set in. A vegetative state with continuous myoclonus characterizes the final stage and most patients die in status epilepticus before age 30 1 .
The neuropathology of LD is characterized by progressive formation and growth of Lafora bodies (LB) in neuronal somata and processes, and by neurodegeneration 1 . LB are composed of aggregates of a variety of proteins and an abnormal form of glycogen that lacks normal glycogen's normal branching and spherical structure essential to its solubility. The abnormal glycogen, called polyglucosan, makes up over 70% of a LB 2 . Whether LB are pathogenic, or a mere epiphenotype, remains uncertain.
LD is caused by loss of function of either of two interacting enzymes, malin, a ubiquitin E3 ligase, and laforin, a phosphatase 3 . Malin regulates the amount of laforin, and laforin regulates glycogen phosphorylation. The latter is essential to normal glycogen structure, through mechanisms that remain poorly defined [3] [4] [5] . Based mostly on cell culture experiments, several additional functions, unrelated to glycogen metabolism, have been tentatively attributed to laforin and malin, including tau kinase dephosphorylation, Wnt signaling regulation, and others [6] [7] [8] [9] . It is possible that loss of one or more of these functions, rather than effects on glycogen metabolism and LB formation, underlie the neurodegeneration and PME of LD.
PTG is an adaptor protein that mediates dephosphorylation of the glycogen synthesizing (glycogen synthase; GS) and degrading (glycogen phosphorylase; GP) enzymes by the pleiotropic phosphatase PP1, which activates GS, inactivates GP, and thus increases glycogen production 10 . We recently hypothesized that, malstructured though they are, polyglucosans are glycogen, and reducing glycogen synthesis might reduce LB formation, which, if LB cause the disease, might prevent LD. As a test of this hypothesis, we removed PTG from the laforin-deficient mouse model of LD (laforin knockout; LKO) by crossing PTG knockout mice with the LD mice. This resulted in drastic reduction of LB and rescued the neurodegeneration of the LD mice 11 . While these results supported the view that LB are pathogenic, there remained the possibility that PTG has adaptor or other functions outside of glycogen metabolism and that its removal prevented neurodegeneration through pathways unrelated to glycogen metabolism and LB. Furthermore, the study was of short duration and did not assess whether the correction of the neurodegeneration is maintained. To address these two issues, we removed GS itself from LKO mice and found that the absence of glycogen synthesis alone was sufficient to prevent LB formation, neurodegeneration, and seizure susceptibility, and do so long-term.
Methods

Mice
All animal procedures were approved by the Toronto Centre for Phenogenomics and Ball State University animal care committees. The LD mouse model in this study is the previously described 11, 12 Epm2a -/-LKO model (mixed C57BL/6J and 129Sv/J).
Mice and humans have two GS isoforms, GYS2 expressed in liver, and GYS1 in most other tissues, including brain. Extrahepatic glycogen is not essential to murine life postnatally: Gys1
) results in perinatal lethality in 90% of cases but 10% survive birth, and these thereafter thrive, including in having normal exercise capacity [13] [14] [15] . To obtain laforin-GS double knockout mice (DKO), we crossed Epm2a -/-mice with Gys1 -/-mice (mixed C57BL/6J and 129Sv/J). 
Double heterozygotes (Epm2a
+/- /Gys1 +/- )
Pathology
For light microscopy, mice were sacrificed by cervical dislocation and tissues fixed in 10% formalin.
Periodic acid-Schiff staining following diastase pretreatment (PASD) was used to stain LB and assess LB load, and glial fibrillary acidic protein (GFAP) immunostaining was used to assess the extent of gliosis, as previously described 11 . For electron microscopy (EM), mice were perfused through the left ventricle of the heart with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), with subsequent processing as described previously 11 .
RESULTS
Laforin and GS double knockout mice have no LB, neurodegeneration, or gliosis
LKO mice had the previously documented 11, 12 profuse amounts of LB in brain and skeletal muscle.
DKO mice, like WT, had none (Fig. 1A-F) . LKO mice had the previously described increased astrocytes and gliosis 11, 12 . DKO mice did not and were no different from WT ( Fig. 1G-I ).
Neurodegeneration in LKO mice does not involve apoptosis or necrosis -it is instead characterized, as observed under EM, by loss of neuronal cytoplasmic fullness, shrinking and darkening of neurons, nuclear and cytoplasmic membrane retraction, and loss of synaptic architecture and contacts at the retracted cell membranes 11, 12 . The LKO mice of this study showed these features, while the DKO mice did not and were no different than their WT controls (Fig. 2) .
DKO mice have no increased seizure susceptibility
LD mouse models closely recapitulate the pathology of LD, including widespread LB formation and neurodegeneration but only modestly reproduce the clinical features of the disease. Their behavioral and epileptic abnormalities are mild, and are highly affected by genetic background. Small differences between LKO mice and WT were originally reported in anxiety (startle response), memory (passive avoidance), balance (rotorod), and muscle strength tests 12 . We were unable to replicate these results in the current LKO mice bred into the genetic background of the Gys1 -/-mice (the LKO mice were no different than WT in this background; data not shown). Spontaneous convulsive seizures do occur in LKO mice but their frequency is too low to use as a reliable outcome measure. Finally, myoclonus was a distinguishing feature between LKO mice and WT controls in our previous study in which LKO mice were bred into the PTG knockout background 11 , but this was no longer the case in the present
A recent study demonstrated that sensitivity to seizure induction by kainic acid clearly distinguishes LD mice from WT 16 . We found this to apply to our present mice in the Gys1 -/-genetic background. We therefore utilized this test to determine whether DKO mice were seizure-susceptible.
While LKO mice were highly sensitive to kainic acid seizure induction, DKO mice were not, and were no different from WT (Fig. 3) .
DISCUSSION
Lafora, 102 years ago, identified LB in the brains of patients with a PME, the genetics, neurological, and neuropathological features of which he described in near-comprehensive detail. His and subsequent human pathological studies showed that LB are present in profuse quantities in the neuropils of patients with active LD, often completely replacing the cytoplasms of countless neuronal processes 1 . These observations long suggested a pathogenic role for LB in the disease. The present work corroborates this, establishing that, at least in the disease's standard mouse model, generation of polyglucosans and LB are necessary to the neurodegeneration and seizure susceptibility -when polyglucosan generation and LB formation are absent, LKO mice no longer exhibit neurodegeneration and are no longer sensitive to kainic acid induced seizures, even at advanced age.
The demonstration that LB formation is dependent on glycogen synthesis opens crucial therapeutic possibilities for LD. Humans who have total absence of hepatic (Glycogenosis 0a) 18 or extrahepatic (Glycogenosis 0b) 19 GS (i.e. GYS2 or GYS1 respectively) are healthy except for osteopenia in the former and a late-childhood cardiomyopathy in the latter; their parents, with 50% GS activities, are completely healthy. While in the present study murine extrahepatic GS was removed completely for the purpose of unambiguously establishing the critical role of glycogen synthesis in LB formation, in our preceding study GS activity had only been partially reduced (by approximately 30%) through removal of PTG, which inhibits GS by promoting its phosphorylation. In that study, there was no cardiac or other disease, and LB, neurodegeneration, and myoclonus were still eliminated 11 ,
suggesting that partial GS reduction might suffice to prevent LD. There are a number of compounds that are known to partially inhibit GS, including sirolimus which is in clinical use in another neurological disease (tuberous sclerosis), and which leads to GS phosphorylation and glycogen reduction by ~30% in certain tissues tested (brain not yet tested) 20 . These and new GS inhibitors that can be identified through high throughput small molecule screens could prove useful in halting LD early in its course, or preclinically, and prevent its devastating progression. LKO mice exhibit a much more severe epileptic response to kainic acid than WT. DKO mice are similar to WT. n = 3-8 mice per genotype, 20-26 months of age. Data is shown as means ± SEM and significance calculated using an unpaired student's t-test.
